The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1678
ISSUE 1678
June 12, 2023
Issue 1678
- Drugs for Migraine
- Comparison Table: Triptans for Migraine (online only)
- Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)
- Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)
- Sotorasib (Lumakras) for NSCLC (online only)
- In Brief: Brexucabtagene autoleucel (Tecartus) for Acute Lymphoblastic Leukemia (online only)
- Asciminib (Scemblix) for Chronic Myeloid Leukemia (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Drugs for Migraine
June 12, 2023 (Issue: 1678)
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without...more
- J Ailani et al. The American Headache Society consensus statement: Update on integrating new migraine treatments into clinical practice. Headache 2021; 61:1021. doi:10.1111/head.14153
- MJ Prior et al. A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. Headache 2010; 50:819. doi:10.1111/j.1526-4610.2010.01638.x
- CC Suthisisang et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 2010; 50:808. doi:10.1111/j.1526-4610.2010.01635.x
- C Suthisisang et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 2007; 41:1782. doi:10.1345/aph.1k121
- C Chen et al. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Headache 2015; 55:265. doi:10.1111/head.12483
- S Alwan et al. Paracetamol use in pregnancy – caution over causal inference from available data. Nat Rev Endocrinol 2022; 18:190. doi:10.1038/s41574-021-00606-x
- S Law et al. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst Rev 2016; 4:CD008541. doi:10.1002/14651858.cd008541.pub3
- CJ Derry et al. Sumatriptan (all routes of administration) for acute migraine attacks in adults – overview of Cochrane reviews. Cochrane Database Syst Rev 2014; 5:CD009108. doi:10.1002/14651858.cd009108.pub2
- G Roberto et al. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. Cephalalgia 2014; 34:5. doi:10.1177/0333102413499649
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Y Orlova et al. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol 2018; 75:566. doi:10.1001/jamaneurol.2017.5144
- K Nezvalová-Henriksen et al. Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013; 28:759. doi:10.1007/s10654-013-9831-x
- US National Library of Medicine. Drugs and Lactation Data-base (LactMed). Available at: https://bit.ly/3MjOzAs. Accessed May 24, 2023.
- Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine. Med Lett Drugs Ther 2020; 62:35.
- Rimegepant (Nurtec ODT) for acute treatment of migraine. Med Lett Drugs Ther 2020; 62:70.
- Zavegepant (Zavzpret) for acute treatment of migraine. Med Lett Drugs Ther 2023 (in press).
- JH VanderPluym et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA 2021; 325:2357. doi:10.1001/jama.2021.7939
- R Croop et al. Zavegepant nasal spray for the acute treatment of migraine: a phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache 2022; 62:1153. doi:10.1111/head.14389
- RB Lipton et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol 2023; 22:209. doi:10.1016/s1474-4422(22)00517-8
- C-P Yang et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systemic review and meta-analysis. JAMA Netw Open 2021; 4:e2128544. doi:10.1001/jamanetworkopen.2021.28544
- TE Baker et al. Human milk and plasma pharmacokinetics of single-dose rimegepant 75 mg in healthy lactating women. Breastfeed Med 2022; 17:277. doi:10.1089/bfm.2021.0250
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Ubrogepant. [Updated 2020 Oct 19]. Available from: https://bit.ly/43kKnqO. Accessed May 24, 2023.
- MJA Láinez et al. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007; 14:269. doi:10.1111/j.1468-1331.2006.01594.x
- SD Silberstein et al. Dihydroergotamine (DHE) – then and now: a narrative review. Headache 2020; 60:40. doi:10.1111/head.13700
- A new dihydroergotamine nasal spray (Trudhesa) for migraine. Med Lett Drugs Ther 2021; 63:204.
- MJ Marmura et al. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache 2015; 55:3. doi:10.1111/head.12499
- JR Saper and AN Da Silva. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs 2013; 27:867. doi:10.1007/s40263-013-0081-y
- EA MacGregor et al. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: results of a new analysis of data from five previously published studies. Gend Med 2010; 7:88. doi:10.1016/j.genm.2010.04.006
- WM Mulleners et al. Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia 2015; 35:51. doi:10.1177/0333102414534325
- F Ashtari et al. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008; 118:301. doi:10.1111/j.1600-0404.2008.01087.x
- S Silberstein et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009; 49:1153. doi:10.1111/j.1526-4610.2009.01508.x
- In brief: Warning against use of valproate for migraine prevention during pregnancy. Med Lett Drugs Ther 2013; 55:45.
- J Weston et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 2016; 11:CD010224. doi:10.1002/14651858. cd010224.pub2
- JR Couch et al. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011; 51:33. doi:10.1111/j.1526-4610.2010.01800.x
- S Tarlaci. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol 2009; 32:254. doi:10.1097/wnf.0b013e3181a8c84f
- LB Kisler et al. Individualization of migraine prevention: a randomized controlled trial of psychophysical-based prediction of duloxetine efficacy. Clin J Pain 2019; 35:753. doi:10.1097/ajp.0000000000000739
- Erenumab (Aimovig) for migraine prevention. Med Lett Drugs Ther 2018; 60:101.
- Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention. Med Lett Drugs Ther 2018; 60:177.
- Eptinezumab (Vyepti) for migraine prevention. Med Lett Drugs Ther 2020; 62:85.
- Atogepant (Qulipta) for migraine prevention. Med Lett Drugs Ther 2021; 63:169.
- R Croop et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021; 397:51. doi:10.1016/s0140-6736(20)32544-7
- PJ Goadsby et al. Long-term efficacy and safety of erenumab: results from 64 weeks of the LIBERTY study. Neurology 2021; 96:e2724. doi:10.1212/wnl.0000000000012029
- MD Ferrari et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 2019; 394:1030. doi:10.1016/s0140-6736(19)31946-4
- DK Kuruppu et al. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments. BMC Neurol 2021; 21:175. doi:10.1186/s12883-021-02196-7
- M Ashina et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2022; 21:597. doi:10.1016/s1474-4422(22)00185-5
- JM Pavlovic et al. Efficacy and safety of erenumab in women with a history of menstrual migraine. J Headache Pain 2020; 21:95. doi:10.1186/s10194-020-01167-6
- In brief: Erenumab (Aimovig) hypersensitivity. Med Lett Drugs Ther 2019; 61:48.
- In brief: Hypertension with erenumab (Aimovig). Med Lett Drugs Ther 2021; 63:56.
- M Ruiz et al. Alopecia as an emerging adverse event to CGRP monoclonal antibodies: cases series, evaluation of FAERS, and literature review. Cephalalgia 2023; 43:3331024221143538. doi:10.1177/03331024221143538
- Botulinum toxin for chronic migraine. Med Lett Drugs Ther 2011; 53:7.
- S Holland et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78:1346. doi:10.1212/wnl.0b013e3182535d0c
- BJ Gales et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother 2010; 44:360. doi:10.1345/aph.1m312
- LJ Stovner et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 2014; 34:523. doi:10.1177/0333102413515348
- JL Jackson et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015; 10:e0130733. doi:10.1371/journal.pone.0130733
- J-Y Bae et al. Cognitive behavioral therapy for migraine headache: a systematic review and meta-analysis. Medicina (Kaunas) 2021; 58:44. doi:10.3390/medicina58010044
- Y Nestoriuc et al. Biofeedback treatment for headache disorders: a comprehensive efficacy review. Appl Psychophysiol Biofeedback 2008; 33:125. doi:10.1007/s10484-008-9060-3
- S-Q Fan et al. Efficacy of acupuncture for migraine prophylaxis: a trial sequential meta-analysis. J Neurol 2021; 268:4128. doi:10.1007/s00415-020-10178-x
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1678
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.